Gilead up 6% after hours on remdesivir buzz in COVID-19

• STAT reports that preliminary results from a study in Chicago evaluating Gilead Sciences' (NASDAQ:GILD) remdesivir in severely ill COVID-19 patients are positive with rapid recoveries in fever and respiratory symptoms observed and almost all patients discharged in less than a week.
• The news is lifting shares, up 6% after hours, a welcome bit of good news on the heels of two canceled studies in China due to low enrollment.